Literature DB >> 9372314

Can a serotonin type 3 (5-HT3) receptor antagonist reduce experimentally-induced itch?

E Weisshaar1, B Ziethen, H Gollnick.   

Abstract

BACKGROUND: Serotonin type 3 (5-HT3) receptor antagonists have been reported to be a novel therapeutic principle for the treatment of cholestatic and uremic pruritus.
OBJECTIVE: To determine the antipruritic effect of a 5-HT3 receptor antagonist (tropisetron) on histamine and serotonin-induced itch under experimental conditions in comparison to native skin and after pretreatment with an orally applied antihistamine (cetirizine).
METHODS: Histamine and serotonin were iontophoretically applied in 10 healthy volunteers. Wheals and flares were planimetrically evaluated. Itching and burning sensations were entered on a scale over 24 min. The examination also comprised alloknesis, elicitation of perifocal itch sensation by usually non-itching (e.g. mechanical) stimuli.
RESULTS: Tropisetron did not have any significant influence on histamine-induced reactions but could significantly reduce serotonin-induced flares. Cetirizine led to a significant reduction of all histamine-induced parameters and abolished serotonin-induced wheals.
CONCLUSIONS: Serotonin has an own pruritic potency and does not only act over histamine containing mast cells. The antipruritic effect of tropisetron reported in cholestatic and uremic pruritus could not be verified in healthy persons under experimental conditions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9372314     DOI: 10.1007/s000110050213

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  30 in total

1.  Structural basis of the anti-inflammatory activity of quercetin: inhibition of the 5-hydroxytryptamine type 2 receptor.

Authors:  Alejandra Ester Rotelli; Carlos Fernando Aguilar; Lilian Eugenia Pelzer
Journal:  Eur Biophys J       Date:  2009-04-26       Impact factor: 1.733

2.  Responsiveness of C neurons in rat dorsal root ganglion to 5-hydroxytryptamine-induced pruritic stimuli in vivo.

Authors:  Junichi Hachisuka; Hidemasa Furue; Masutaka Furue; Megumu Yoshimura
Journal:  J Neurophysiol       Date:  2010-05-19       Impact factor: 2.714

3.  Characterization of pruriceptive trigeminothalamic tract neurons in rats.

Authors:  Hannah R Moser; Glenn J Giesler
Journal:  J Neurophysiol       Date:  2014-01-29       Impact factor: 2.714

4.  Role of neurturin in spontaneous itch and increased nonpeptidergic intraepidermal fiber density in a mouse model of psoriasis.

Authors:  Kent Sakai; Kristen M Sanders; Marina R Youssef; Kevin M Yanushefski; Liselotte E Jensen; Gil Yosipovitch; Tasuku Akiyama
Journal:  Pain       Date:  2017-11       Impact factor: 6.961

5.  Effect of mirtazapine on pruritus in patients on hemodialysis: a cross-over pilot study.

Authors:  Mahmoud Gholyaf; Vida Sheikh; Fatemeh Yasrebifar; Younes Mohammadi; Mahtabalsadat Mirjalili; Maryam Mehrpooya
Journal:  Int Urol Nephrol       Date:  2020-05-07       Impact factor: 2.370

Review 6.  Trp channels and itch.

Authors:  Shuohao Sun; Xinzhong Dong
Journal:  Semin Immunopathol       Date:  2015-09-18       Impact factor: 9.623

Review 7.  Peripheral and Central Mechanisms of Itch.

Authors:  Xintong Dong; Xinzhong Dong
Journal:  Neuron       Date:  2018-05-02       Impact factor: 17.173

8.  Four Possible Itching Pathways Related to the TRPV1 Channel, Histamine, PAR-2 and Serotonin.

Authors:  Hiroshi Nakagawa; Akio Hiura
Journal:  Malays J Med Sci       Date:  2013-07

Review 9.  The Return of the Mast Cell: New Roles in Neuroimmune Itch Biology.

Authors:  Fang Wang; Ting-Lin B Yang; Brian S Kim
Journal:  J Invest Dermatol       Date:  2020-04-02       Impact factor: 8.551

10.  Scratching behavior and Fos expression in superficial dorsal horn elicited by protease-activated receptor agonists and other itch mediators in mice.

Authors:  Tasuku Akiyama; Austin W Merrill; Karen Zanotto; Mirela Iodi Carstens; E Carstens
Journal:  J Pharmacol Exp Ther       Date:  2009-03-17       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.